April 1, 2020
The Ministry of Health, Labor and Welfare (MHLW) on March 31 ordered label revisions for a batch of drugs including MSD’s PD-1 inhibitor Keytruda (pembrolizumab) and Shionogi’s influenza medicine Xofluza (baloxavir marboxil). Keytruda will newly add the risk of toxic...read more